Connect with us

Health

Lawsuits ramp up pressure on family that owns opioid company

Editor

Published

on

The legal pressure on the prominent family behind the company that makes OxyContin, the prescription painkiller that helped fuel the opioid epidemic in the U.S., is likely to get more intense.

The Sackler family came under heavy scrutiny this week when a legal filing in a Massachusetts case gave detailed allegations that they and company executives sought to push prescriptions of the drug and downplay its risks. Those revelations are likely to be a preview of the claims in a series of expanding legal challenges.

Members of the family that controls Connecticut-based Purdue Pharma already are defendants in a lawsuit brought by New York’s Suffolk County.

Paul Hanly, a lawyer representing the county, said he expects to add the Sacklers to other opioid suits filed across the country. He explained last year that he was targeting the family, known for its donations to some of the world’s great museums and universities, in part because they took “tens of billions” of dollars out of Purdue.

Looming as potentially the biggest legal and financial risk for the family is a massive consolidated federal case playing out in Ohio.

More than 1,000 government entities have sued Purdue, along with other drugmakers and distributors, claiming they are partly culpable for a drug overdose crisis that resulted in a record 72,000 deaths in 2017. The majority of those deaths were from legal or illicit opioids.

The company documents at the heart of the Massachusetts claims also could be evidence in the Ohio lawsuits, which are being overseen by a federal judge. The allegations ramp up pressure on the industry — and perhaps the Sacklers — to reach a settlement, said Paul Nolette, a political science professor at Marquette University who studies the role of state attorneys general.

The Sackler name adorns the Metropolitan Museum of Art in New York, but the family’s ties to the powerful painkiller OxyContin are bringing a new kind of attention to the Sacklers and their philanthropic legacy. (Seth Wenig/Associated Press)

Having Sackler family members named as defendants in Massachusetts “indicates that the government attorneys believe they have the ‘smoking guns’ necessary to broaden the potential liability of those at the top of the organization,” he said in an email.

The allegations could tarnish a name that is best known for its generosity to museums worldwide including New York’s Metropolitan Museum of Art, which has a Sackler wing, and London’s Tate Modern. The Sackler name also is on a gallery at the Smithsonian, a wing of galleries at London’s Royal Academy of Arts and a museum at Beijing’s Peking University. The family’s best known and most generous donor, Arthur M. Sackler, died nearly a decade before
OxyContin was released.

The Cleveland-based judge, Dan Polster, has been pushing for a settlement since he took over the federal cases a year ago, arguing that the parties involved should find ways to end this man-made crisis, rather than hold years of trials. A court order prohibits participants from discussing most aspects of settlement talks publicly.

In its lawsuit filed last year, the Massachusetts attorney general’s office went after members of the Sackler family and Purdue, which is structured as a partnership and is not publicly traded.

‘Blizzard of prescriptions’

The company’s flagship drug, OxyContin, was the first of a generation of drugs that used a narcotic painkiller in a time-release form. That meant each pill had a larger amount of drug in it than other versions and could get abusers a more intense high if they defeated the time-release process.

Many of the attorney general’s specific allegations  based on company documents — were blacked out at the request of Purdue and the Sackler family. The state recently filed a new version of its complaint that made public many of their allegations for the first time.

The state is asserting that Richard Sackler, a son of a company founder and at the time a senior vice-president for Purdue, as well as other family members pushed selling OxyContin even when they knew it could cause problems. When the drug was first sold in 1996, the filing said, Sackler told the sales force “the launch of OxyContin Tablets will be followed by a blizzard of prescriptions that will bury the competition.”

In 2007, the company and three current and former executives pleaded guilty to criminal charges that they deceived regulators, doctors and patients about the drug’s addiction risks. The company agreed to fines of $634 million US.

The next year, according to the Massachusetts lawsuit, the company pressed ahead with a new version of the drug designed to be harder for abusers to crush. It did so without first conducting trials and despite a warning from the company’s CEO that the new version “will not stop patients from the simple act of taking too many pills.”

Purdue responded to the Massachusetts filing with a strong statement: “In a rush to vilify a single manufacturer whose medicines represent less than 2 per cent of opioid pain prescriptions rather than doing the hard work of trying to solve a complex public health crisis, the complaint distorts critical facts and cynically conflates prescription opioid medications with illegal heroin and fentanyl.”

A spokesman for the Sackler family declined to comment separately.

Abbe Gluck, a Yale law professor who is following the federal case in Ohio, said the documents could make Purdue seem more liable or bring the Sackler family into the case in a way that presents obstacles to a settlement. But she said that might not change things for the other companies involved.

 “The drug companies have an interest in settling their own claims globally,” she said.

Source link

قالب وردپرس

Health

Post-vaccine surge? Michigan’s spring coronavirus case spike close to previous year’s autumn high

Editor

Published

on

By

(Natural News) The spike in new Wuhan coronavirus infections recorded in Michigan over the spring is similar to a spike seen during the 2020 fall season. According to a Wall Street Journal analysis, the state’s daily coronavirus case count averaged more than 7,000 for almost two weeks – before taking a slight dip to 6,891 on April 20. This echoed similar figures back in November and December 2020, which saw sharp rises in infections for those two months before plunging.

Back in autumn of last year, Michigan averaged more than 7,000 cases per day for a span of 10 days. New infections dropped slightly, then briefly spiked as the December holidays approached. It then fell to the low 1,000s for the succeeding two months – until ascending again in March.

According to University of Michigan internal medicine professor Dr. Vikas Parekh, the sudden increase in new infections could be attributed to several factors. Among the factors he cited was re-openings, which increased people’s interactions and mobility. Parekh said the loosened restrictions contributed to the spread of the highly contagious U.K. B117 variant.

“As the B117 variant spreads nationally, we will likely see other stats [with] their own surges – although I hope none are as bad as Michigan,” the professor remarked. He continued: “The milestone just tells us we are not yet in the clear, especially as we still have large portions of our population who are not vaccinated yet.”

Parekh also expressed optimism over the lower daily caseloads the Great Lakes State reported. He said he believes both cases and hospitalizations have plateaued and will likely decline soon. The professor commented: “[COVID-19] positivity has been declining now for one week, which is usually a leading indicator of case decline.”

Meanwhile, the state cited younger populations and youth sports, such as basketball, wrestling and hockey, to increase new COVID-19 infections. Because of this, Gov. Gretchen Whitmer called to suspend youth sports and indoor dining in the state. She also exhorted high schools to conduct remote class sessions for two weeks to curb the spread of the pathogen.

Michigan still experienced the spike in cases despite having one of the highest vaccination rates in the country

During the opening stages of the U.S.’s immunization drive against COVID-19, Michigan boasted of having one of the highest vaccination rates nationwide. A report by Bridge Michigan even noted the initial “frenzy for vaccines” that “far exceeded the state’s limited supply.” But things have appeared to turn around for Michigan, as it now struggles to reach the 70 percent vaccination rate needed for herd immunity.

Continue Reading

Health

Scottish mom’s legs turn into a pair of “giant blisters” after first dose of AstraZeneca’s coronavirus vaccine

Editor

Published

on

By

(Natural News) Sarah Beuckmann of Glasgow, Scotland, felt a tingling sensation in her legs and noticed a rash flaring up around her ankles a week after getting her first dose of AstraZeneca’s coronavirus (COVID-19) vaccine on March 18.

She also had flu-like symptoms right after the vaccination.

Beuckmann called her doctor to arrange an appointment the morning she noticed the rash, but by the afternoon her skin was already breaking out into blood-filled blisters. Blisters also appeared on her legs, hands, face, arms and bottom.

“I ended up asking my husband to take me to A&E,” said Beuckmann, referring to “accident and emergency,” the equivalent of an emergency room (ER). “When I got there, my heart rate was sitting at 160bpm, which they were very concerned about. I got put on an ECG machine.”

Doctors determine AstraZeneca’s COVID-19 vaccine triggers the rash

Medics carried out tests for HIV, herpes and other skin conditions to work out what triggered the rash, but all results came back negative. Doctors finally determined that the vaccine caused her rare reaction after carrying out two biopsies.

“Once they found that it was a reaction to the vaccine, they put me on steroids and that really seems to be helping my progress,” said Beuckmann. She had been advised by her doctor not to get the second dose of AstraZeneca’s COVID-19 vaccine because of her reaction.

Beuckmann spent 16 days at Queen Elizabeth University Hospital. She was discharged to recover at home. The 34-year-old mother of one is currently wheelchair-bound due to the bandages on her legs and blisters on the soles of her feet. She may need physiotherapy to help strengthen her leg muscles.

“They are starting to heal and they’re looking a lot better than they were but as the blisters started to get worse, they all sort of merged together,” she said. “I didn’t know what was going on.”

With the blisters merging, her legs have looked like a pair of “giant blisters.” Beuckmann admitted that at one point she feared her legs might have to be amputated.

Dermatologist agrees COVID-19 vaccine causes the blisters

Dr. Emma Wedgeworth, a consultant dermatologist and spokeswoman at the British Skin Foundation, agreed that Beuckmann had likely suffered a reaction to the vaccine.

“Vaccines are designed to activate the immune system. Occasionally people will have quite dramatic activation of their immune systems which, as happened in this case, can manifest in their skin” Wedgeworth told MailOnline. “This poor lady had a very severe reaction, which thankfully is extremely rare.”

It is not clear why Beuckmann, who works in retail, was invited for a vaccine. Scotland’s vaccine rollout was focused on people over the age of 50 when she got vaccinated, although vaccines are available to those who are considered at risk from the virus, or live with someone considered vulnerable.

At least 20 million Briton have had AstraZeneca’s COVID-19 vaccine, which drug regulators say causes a rash in one percent of cases. They say rashes caused by the jab tend to go away within a week.

Continue Reading

Health

Trojan labs? Chinese biotech company offers to build COVID testing labs in six states

Editor

Published

on

By

In 2012, BGI acquired Complete Genomics, a DNA sequencing company and equipment maker. The funds for the $117.6 million purchase were raised from Chinese venture capitals. The company has expanded its footprint globally. According to its website, BGI conducts business in more than 100 countries and areas and has 11 offices and labs in the U.S.

People are concerned about China’s access to American DNA data

Some said that with Complete Genomics providing an American base, BGI would have access to more DNA samples from Americans, helping it compile a huge database of genetic information. Some also worried about the protection of the genetic information’s privacy.

According to a 2019 report from the U.S.–China Economic and Security Review Commission (USCC), BGI “has formed numerous partnerships with U.S. healthcare providers and research organizations to provide large-scale genetic sequencing to support medical research efforts,”

There are three main reasons why many people in the biotech community and government have expressed concerns about China’s access to American DNA data.

In the “60 Minutes” interview, Evanina discussed the very likely scenario in which Chinese companies would be able to micro-target American individuals and offer customized preventative solutions based on their DNA.

Evanina asked: “Do we want to have another nation systematically eliminate our healthcare services? Are we okay with that as a nation?”

The second concern is that China may use DNA to track and attack American individuals. As the USCC report states: “China could target vulnerabilities in specific individuals brought to light by genomic data or health records. Individuals targeted in such attacks would likely be strategically identified persons, such as diplomats, politicians, high-ranking federal officials or military leadership.”

The third concern is that China may devise bioweapons to target non-Asians. Steven Mosher, president of the Population Research Institute, discussed it in his article “What Will China Do With Your DNA?” published by The Epoch Times in March 2019.

He wrote: “We know that the Asian genome is genetically distinct from the Caucasian and African in many ways. … Would it be possible to bioengineer a very virulent version of, say, smallpox, that was easily transmitted, fatal to other races, but to which the Chinese enjoyed a natural immunity? … Given our present ability to manipulate genomes, if such a bio-weapon can be imagined, it can probably – given enough time and resources – be realized.”

An article from Technocracy said: “China’s aggressive collection of American DNA should be doubly alarming because it can only spell one ultimate outcome: biowarfare. That is, genetically engineering viruses or other diseases that will be selectively harmful to U.S. populations.”

Continue Reading

Chat

Trending